Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

It's a Late Breaking Abstract! Per ESMO

Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.
Only abstracts for which no conclusive data are available at the time of the abstract submission deadline of 10 May 2017 will be considered for late-breaking status.

A skeleton indicating the type of data that will be available by the late-breaking abstract deadline must be submitted online by the regular abstract deadline.

Submitters of preliminary versions receiving approval to proceed must submit the final LBA by 19 July 2017, 21:00 CEST (Central European Summer Time)

As for my expectations, I'm not expecting anything that will move the stock higher (but I hope I'm sooo wrong w that opinion). Here's a repost of my comment regarding on why based on what I heard at the RBC Healthcare Conference on Feb 23rd

Regarding Poziotinib, last year at this very conference, Raj was effusive w regards to the Korean P2 trial in metastatic breast cancer. That open label study stopped recruiting in Feb 2016 so you would think we may have heard something by now. In an earlier post, I mentioned that if we didn’t hear anything by ASCO in June than the Korean results are nothing to get excited about...

...Meanwhile, what to make of this pivot w regards to poziotinib away from metastatic BC? I don’t think the results they got in the Korean P2 study will be applicable to the US P2 in mBC since the pts in the US trial are getting double the dose. Still Raj barely mentioned it so it makes one wonder. Hopefully we’ll hear more at the quarterly.

There's a big caveat with not expecting inspiring results w the Korean study and that is I never did my homework on what is PFS and OS on SoC for metastatic BC but my uninformed opinion on that is that when you think metastatic it's a much shorter time-frame.